Skandinaviska Enskilda Banken AB publ purchased a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 38,035 shares of the company's stock, valued at approximately $647,000. Skandinaviska Enskilda Banken AB publ owned 0.07% of Bicara Therapeutics at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the business. First Turn Management LLC bought a new stake in Bicara Therapeutics in the third quarter valued at about $14,324,000. The Manufacturers Life Insurance Company acquired a new stake in Bicara Therapeutics during the third quarter valued at approximately $582,000. FMR LLC bought a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at approximately $57,913,000. Walleye Capital LLC acquired a new position in shares of Bicara Therapeutics in the 3rd quarter worth approximately $809,000. Finally, Vestal Point Capital LP bought a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $10,825,000.
Wall Street Analyst Weigh In
A number of analysts have weighed in on BCAX shares. Wedbush reiterated an "outperform" rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. HC Wainwright upped their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, January 27th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $36.50.
Read Our Latest Research Report on BCAX
Bicara Therapeutics Stock Up 1.1 %
Shares of Bicara Therapeutics stock traded up $0.15 during trading on Friday, reaching $13.24. The company's stock had a trading volume of 478,063 shares, compared to its average volume of 457,175. The stock has a 50-day moving average of $12.98. Bicara Therapeutics Inc. has a one year low of $11.10 and a one year high of $28.09.
Bicara Therapeutics Profile
(
Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Articles
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
